Pent-up demand for the new pancreatic cancer therapy Rasonque helped RevMed soar past analysts’ sales expectations and reach 5,000 patients in the third quarter.
With backing from three Big Pharma investment arms, British biotech T-Therapeutics is brewing up a clinical launch for its cancer and autoimmune T cell engagers.
Evommune is commiting $30 million upfront for Hinova Pharmaceuticals’ oral molecular glue degrader—a low-cost bet with a high probability of success, according to analysts, after clinical failures roiled the biotech’s internal pipeline earlier this year.
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.
Biotech and pharma professionals share job hunt challenges after being let go, while a recruiting expert discusses why hiring managers prefer candidates without employment gaps and how to address gaps in interviews.
The Internal Revenue Service is once again providing an online way to attend its Nationwide Tax Forum series and earn continuing professional education credits.
Florida voters delivered one of the most far-reaching property-tax cuts in years, handing homeowners relief while threatening to blow holes in local budgets.
A Brooklyn appeals court threw out a lawsuit challenging the rollout of New York City’s pied-à-terre tax, ruling that the homeowner plaintiffs lacked standing.
Newly emboldened by wins in the midterm elections that shifted control of the House and Senate to their party, Democrats are already gaming their strategy.